- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03404219
Motivation and Skills Support (MASS)
Enhancing Social Functioning in Schizophrenia Through Scalable Mobile Technology
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94132
- San Francisco State University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Boston University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
•All participants with schizophrenia or schizoaffective disorder (identified either by self-report and confirmatory chart diagnosis, or by using the Structured Clinical Interview for DSM-5 [SCID-5]) will be in good general physical health, between 18 and 65 years old (as to not confound developmental issues with our focus), and fluent in English. Subjects do not need to have a significant other in order to participate in the study.
Exclusion Criteria:
•All participants with a current (past 6 months) substance use disorder, which will be determined by administration of the SCID-5, and self-reported current suicidal ideation with intent and/or a plan (assessed using attached instrument; i.e., "High" risk) or diagnosis of a neurological disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention
Mobile intervention (i.e., Ecological momentary intervention [EMI]) addressing social motivation and social skills.
Twice daily notifications sent to deliver EMI content.
Social goal reminders and steps provided to support goal attainment.
Social Skills Training content delivered via brief video clips.
|
Mobile phone-based application to support social skills and social motivation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Social Functioning as Measured by the Social Functioning Scale (SFS)
Time Frame: Baseline (study entry) and follow-up (3 months post-intervention)
|
The Social Functioning Scale (SFS; Birchwood, Smith, Cochrane, Wetton, and Copestake, 1990) is a validated measure of social functioning commonly used in schizophrenia research studies.
This clinician-administered measure consists of 7 sub-scales where higher scores indicate better social functioning: Social Engagement/Withdrawal (7 items.
Score range: 0-15), Interpersonal (5 items.
Score range: 0-30), Prosocial (5 items.
Score range: 0-66), Recreation (23 items.
Score range: 0-48), Independence - competence (15 items.
Score range: 0-39), Independence - performance (13 items.
Score range: 0-39), and Employment (13 items.
Score range is 0-6 if the participant is unemployed and 7-10 if the participant is employed).
The total score is the sum of the 7 sub-scales (Possible range of 0-247) and higher scores indicate better functioning.
The investigators will examine the difference in total score from baseline (study entry) to follow-up (3 months after study termination).
|
Baseline (study entry) and follow-up (3 months post-intervention)
|
|
Changes in Social Engagement as Measured by the Quality of Life Scale (QLS) - Interpersonal Relations Subscale.
Time Frame: Baseline (study entry) and follow-up (3 months post-intervention)
|
The Heinrich Quality of Life Scale - Interpersonal Relations subscale (Heinrichs, Hanlon, & Carpenter, 1984) is a validated measure of social engagement used in studies of schizophrenia.
This clinician-administered measure consists of 8 items that address different facets of social engagement (e.g., social network, acquaintances, intimate relationships, social withdrawal).
Possible scores range from 0-48 with higher scores indicating better outcomes.
The investigators will administer this measure at baseline (study entry) and follow-up (3 months post-intervention).
|
Baseline (study entry) and follow-up (3 months post-intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Experience-Sampling-Based Self-Reports of Social Appraisals
Time Frame: 2 times per day for 2 months (intervention period).
|
The investigators will ask participants to report on positive social appraisals (unpublished measure) of recent interactions 2 times per day over the 2-month intervention period. Specific items and response options are the following:
|
2 times per day for 2 months (intervention period).
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel Fulford, PhD, CRC BU Univeristy
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R21MH111501-01 (NIH)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States, India
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Bradley LegaRecruiting
-
Central Institute of Mental Health, MannheimRecruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
-
Shanghai Zhongze Therapeutics Co., Ltd.Yale UniversityNot yet recruiting
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
Clinical Trials on Motivation and Skills Support (MASS)
-
Hospices Civils de LyonRecruiting
-
Mersin UniversityCompleted
-
Charles Drew University of Medicine and ScienceWithdrawnCancer | Breast Cancer | Lung Cancer | Colon Cancer | Caregiver BurnoutUnited States
-
Charles Drew University of Medicine and ScienceNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Elif BakırCompletedType 1 DiabetesTurkey
-
Syracuse UniversityNational Institute of Mental Health (NIMH)CompletedHIV Infections | Child Abuse, SexualUnited States
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedHIV Infections | Sexually Transmitted DiseasesUnited States
-
Saglik Bilimleri UniversitesiCompletedBreastfeeding Counseling Based on Motivational InterviewingTurkey (Türkiye)
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Rhode Island HospitalCompletedHIV | Medication Adherence | Mobile HealthUnited States